IDEAYA Biosciences (IDYA)
(Delayed Data from NSDQ)
$24.12 USD
-0.88 (-3.52%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $24.13 +0.01 (0.04%) 4:58 PM ET
4-Sell of 5 4
F Value F Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
IDYA 24.12 -0.88(-3.52%)
Will IDYA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for IDYA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IDYA
Down -8.63% in 4 Weeks, Here's Why You Should You Buy the Dip in IDEAYA Biosciences (IDYA)
IDEAYA Biosciences, Inc. (IDYA) Reports Q4 Loss
IDYA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Sage Therapeutics, Inc. (SAGE) Reports Q4 Loss, Lags Revenue Estimates
All You Need to Know About IDEAYA Biosciences (IDYA) Rating Upgrade to Buy
Wall Street Analysts Predict an 81.88% Upside in IDEAYA Biosciences (IDYA): Here's What You Should Know
Other News for IDYA
Ideaya Biosciences: Moving Into ADCs For Solid Tumors
IDEAYA Biosciences Inc (IDYA) Announces Q2 2025 Financial Results and Key Clinical Updates | ...
IDEAYA Biosciences Inc Reports Q2 2025 EPS of -$0.88 and Revenue of $0, Missing Estimates
Ideaya Biosciences (IDYA) Anticipates Significant Clinical Advances
IDEAYA Biosciences, Inc. Reports Second Quarter 2025 Financial Results and Provides Business ...